arrow
R

Rosalinda H. Arends

Pfizer
H指数:12
被引数:698

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

半衰期延长的新型冠状病毒中和单克隆抗体AZD7442 (tixagevimab-cilgavimab) 在健康成人中的安全性,耐受性和药代动力学

2023-01-2312
OAAI
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

AZD7442 (Tixagevimab/Cilgavimab) 用于症状性冠状病毒疾病的暴露后预防2019

2022-11-2228
OAAI
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
2022-10-01157
OAAI
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
2022-03-09167
OAAI
Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment
2017-05-1924
OAAI